Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S logo
$56.50 +0.40 (+0.70%)
Closing price 03:59 PM Eastern
Extended Trading
$56.44 -0.07 (-0.12%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 16 Analyst Ratings
Sell
1
Hold
12
Buy
3

Based on 16 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 1 has given a sell rating, 12 have given a hold rating, and 3 have given a buy rating for NVO.

Consensus Price Target

$81.00
43.35% Upside
According to the 16 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $81.00. The highest price target for NVO is $160.00, while the lowest price target for NVO is $54.00. The average price target represents a forecasted upside of 43.35% from the current price of $56.51.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVO Analyst Ratings Over Time

TypeCurrent Forecast
8/29/24 to 8/29/25		1 Month Ago
7/30/24 to 7/30/25		3 Months Ago
5/31/24 to 5/31/25		1 Year Ago
8/30/23 to 8/29/24
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
12 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$81.00$112.00$128.00$145.17
Forecasted Upside43.35% Upside123.82% Upside79.27% Upside5.54% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novo Nordisk A/S Stock vs. The Competition

TypeNovo Nordisk A/SMedical CompaniesS&P 500
Consensus Rating Score
2.13
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside44.35% Upside15,720.96% Upside10.25% Upside
News Sentiment Rating
Positive News

See Recent NVO News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/22/2025Dbs Bank
0 of 5 stars		 UpgradeStrong Sell ➝ Hold
8/20/2025Zacks Research
0 of 5 stars		 DowngradeHold ➝ Strong Sell
8/19/2025TD Cowen
4 of 5 stars		Michael Nedelcovych
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$105.00 ➝ $70.00+27.32%
8/13/2025BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderperform ➝ Neutral
8/13/2025BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderperform ➝ Neutral$54.00+8.46%
8/5/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Matthew Weston
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Neutral
7/31/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeStrong-Buy ➝ Hold
7/31/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Rajesh Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Hold$57.00+13.91%
7/30/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Emily Field
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Equal Weight
4/17/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Fernandez
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeStrong-Buy ➝ Hold
4/17/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Evan David Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.00+1.78%
3/13/2025Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Evans
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Buy
3/3/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
2/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageEqual Weight
1/6/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		W. Kapadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeUnderperform ➝ Market Perform
11/6/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00+49.39%
6/10/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$125.00 ➝ $160.00+13.09%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$156.00+17.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:40 PM ET.


Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 27, 2025. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Novo Nordisk:

  • The current stock price is around $55, which may present a buying opportunity for investors looking for value.
  • Recent earnings reports show that Novo Nordisk has consistently beaten analysts' expectations, indicating strong financial performance and effective management.
  • The company has a high return on equity, suggesting efficient use of shareholders' equity to generate profits.
  • With a market capitalization exceeding $246 billion, Novo Nordisk is a major player in the pharmaceutical industry, providing stability and growth potential.
  • Recent investments by institutional investors indicate confidence in the company's future prospects, which can be a positive signal for individual investors.

Novo Nordisk A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Novo Nordisk for these reasons:

  • The stock has experienced significant volatility, with a 52-week high of $139.74 and a low of $45.05, which may concern risk-averse investors.
  • Despite strong earnings, the company's revenue figures have not met some analysts' expectations, which could indicate potential challenges ahead.
  • The current debt-to-equity ratio of 0.52 suggests that the company is moderately leveraged, which could pose risks if market conditions change.
  • Recent dividend cuts may signal financial strain or a shift in company strategy, which could deter income-focused investors.
  • Market competition in the pharmaceutical sector is intense, and any loss of market share could negatively impact future growth prospects.

NVO Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $81.00, with a high forecast of $160.00 and a low forecast of $54.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There is currently 1 sell rating, 12 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 43.35% based on their 12-month stock forecasts.

Over the previous 90 days, Novo Nordisk A/S's stock had 4 downgrades and 3 upgrades by analysts.

Novo Nordisk A/S has been rated by research analysts at Barclays, BNP Paribas, BNP Paribas Exane, Dbs Bank, Hsbc Global Res, HSBC, TD Cowen, UBS Group, and Zacks Research in the past 90 days.

Analysts like Novo Nordisk A/S less than other "medical" companies. The consensus rating for Novo Nordisk A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVO compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:NVO) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel